Novartis lifts full-year profit forecast, announces $10 billion share buyback
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter. The company…